DDInter258 DDInter1925
A synthetic morphinan analgesic with narcotic antagonist action. It is used in the management of severe pain.
Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. After approval, Roche in collaboration with Genentech launched a broad development program.
Butorphanol {u} (Compound) causes {v} (Side Effect) Eye disorder
Eye disorder {u} (Side Effect) is caused by {v} (Compound) Vemurafenib
Butorphanol {u} (Compound) resembles {v} (Compound) Dextromethorphan
Dextromethorphan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vemurafenib
Butorphanol {u} (Compound) resembles {v} (Compound) Naltrexone
Naltrexone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vemurafenib
Butorphanol {u} (Compound) causes {v} (Side Effect) Eye disorder
Eye disorder {u} (Side Effect) is caused by {v} (Compound) Etoricoxib
Etoricoxib {u} (Compound) resembles {v} (Compound) Vemurafenib
Butorphanol {u} (Compound) causes {v} (Side Effect) Back pain
Back pain {u} (Side Effect) is caused by {v} (Compound) Lidocaine
Lidocaine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vemurafenib
Butorphanol {u} (Compound) resembles {v} (Compound) Dextromethorphan
Dextromethorphan {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Vemurafenib
Butorphanol {u} (Compound) resembles {v} (Compound) Levallorphan
Levallorphan {u} (Compound) resembles {v} (Compound) Dextromethorphan
Dextromethorphan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vemurafenib
Butorphanol {u} (Compound) resembles {v} (Compound) Naltrexone
Naltrexone {u} (Compound) downregulates {v} (Gene) MTHFD2
MTHFD2 {u} (Gene) is upregulated by {v} (Compound) Vemurafenib
Butorphanol {u} (Compound) causes {v} (Side Effect) Back pain
Back pain {u} (Side Effect) is caused by {v} (Compound) Mirabegron
Mirabegron {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vemurafenib
Butorphanol {u} (Compound) resembles {v} (Compound) Naltrexone
Naltrexone {u} (Compound) upregulates {v} (Gene) FOXO3
FOXO3 {u} (Gene) is upregulated by {v} (Compound) Vemurafenib
Butorphanol (Compound) causes Eye disorder (Side Effect) and Eye disorder (Side Effect) is caused by Vemurafenib (Compound)
Butorphanol (Compound) resembles Dextromethorphan (Compound) and Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib
Butorphanol (Compound) resembles Naltrexone (Compound) and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib
Butorphanol (Compound) causes Eye disorder (Side Effect) and Eye disorder (Side Effect) is caused by Etoricoxib (Compound) and Etoricoxib (Compound) resembles Vemurafenib (Compound)
Butorphanol (Compound) causes Back pain (Side Effect) and Back pain (Side Effect) is caused by Lidocaine (Compound) and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Vemurafenib
Butorphanol (Compound) resembles Dextromethorphan (Compound) and Dextromethorphan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Butorphanol (Compound) resembles Levallorphan (Compound) and Levallorphan (Compound) resembles Dextromethorphan (Compound) and Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib
Butorphanol (Compound) resembles Naltrexone (Compound) and Naltrexone (Compound) downregulates MTHFD2 (Gene) and MTHFD2 (Gene) is upregulated by Vemurafenib (Compound)
Butorphanol (Compound) causes Back pain (Side Effect) and Back pain (Side Effect) is caused by Mirabegron (Compound) and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Vemurafenib
Butorphanol (Compound) resembles Naltrexone (Compound) and Naltrexone (Compound) upregulates FOXO3 (Gene) and FOXO3 (Gene) is upregulated by Vemurafenib (Compound)